VRTX
Vertex Pharmaceuticals Incorporated
Biotechnology · Healthcare · United States
540.00
close · 2026-10-29
value
34
cheaper than peers34
quality
89
stronger fundamentals89
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 9.65× | 58 |
| EV to EBITDA | 22.23× | 43 |
| forward P/E | 26.48× | 34 |
| price to book | 6.76× | 27 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 38.1% | 92 |
| return on equity | 23.5% | 90 |
| debt to equity | 9.8% | 61 |
| revenue growth | 12.5% | 45 |
4 of 4 measures available
Facts
| market cap | $137B |
| free cash flow | — |
| employees | 6,400 |
| first trade | 1991-07-24 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 15.32 | -2.08 | 13.89 | 12.82 |
| free cash flow | $3.19B | -$978.0M | $3.28B | $3.93B |
| net income | $3.95B | -$535.6M | $3.62B | $3.32B |
| revenue | $12.00B | $11.02B | $9.87B | $8.93B |
| unusual items | -$381.1M | $500,000 | $51.6M | $57.5M |